← Leaderboards
John Zic
Vanderbilt University
$592
Attributed
$592
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$592 · 1
By mechanism
M01$592 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Jennifer A Pietenpol$43,416,854
- Barney S Graham$269,836
- Eugene M. Oltz$20,457,685
- Sebastian Joyce$13,492,547
- Nancy Joan Brown$32,445,188
Others in their field
Top investigators on “Antineoplastics”
- David Heimbrook · Leidos Biomedical Research, Inc.$245,744,647
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Charles A Coltman · Southwest Oncology Group$134,454,243
- Gregory H Reaman · National Childhood Cancer Foundation$112,139,479
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Richard L Schilsky · University Of Chicago$90,728,118
Research focus
AntineoplasticsClinical ResearchClinical Trial Phase IHuman SubjectHuman Therapy EvaluationLymphomaNeoplasm /Cancer ChemotherapyOral AdministrationT Lymphocyte
Grant awards (5)
PHASE I STUDY OF ORAL BCX 34 IN PATIENTS W/ T CELL MALIGNANCIES$0
M01 · FY2002 · RR
PHASE I STUDY OF ORAL BCX 34 IN PATIENTS W/ T CELL MALIGNANCIES$0
M01 · FY2001 · RR
PHASE I STUDY OF ORAL BCX 34 IN PATIENTS W/ T CELL MALIGNANCIES$0
M01 · FY2001 · RR
PHASE I STUDY OF ORAL BCX 34 IN PATIENTS W/ T CELL MALIGNANCIES$0
M01 · FY2001 · RR
PHASE I STUDY OF ORAL BCX 34 IN PATIENTS W/ T CELL MALIGNANCIES$592
M01 · FY2000 · RR